Business Wire

STALICLA Translates its Novel Precision Medicine Approach for Autism Spectrum Disorder into Clinical Development with First Patient in Phase 1b Trial of STP1

Share

STALICLA SA, today announced first patient enrolled in its Phase 1b clinical trial with STP1, a first in class precision medicine for patients within the autism spectrum disorder (ASD) Phenotype 1 subgroup (ASD-Phen1), a novel biological subgroup identified by STALICLA’s proprietary discovery platform. STP1 is a novel combination of compounds: a pan-PDE inhibitor with anti-inflammatory properties and a modulator of NKCC1, specifically targeting the biological dysregulations linked to ASD-Phen1.

Autism spectrum disorder (ASD) is a group of neurodevelopmental disorders (NDDs) currently diagnosed based on core behavioral features, including persistent deficits in social communication and social interaction, restricted and repetitive patterns of behavior, interests, or activities. Significant impairment in daily functioning should also be present. Globally, ASD is highly prevalent and affects approximately 10 million patients in Europe and the United States and more throughout the world. There are no biological criteria for this diagnosis. ASD is characterized by high levels of clinical and genetic heterogeneity, supporting the existence of ASD biological subtypes requiring differential pharmacological treatment strategies.

By combining real-world patient data and its proprietary systems biology and AI-powered drug discovery platform called DEPI (Databased Endophenotyping Patient Identification), STALICLA is uncovering novel patterns of non-behavioral and biologically defined parameters amongst patients with ASD. STALICLA has already identified ASD Phenotype 1, a first subpopulation of patients with idiopathic ASD that can be identified by distinct multi-omics biomarkers. ASD Phenotype 1 is characterized by dysregulation of key intracellular pathways, transcription factors and immune factors. The most recent biomarker data related to ASD Phenotype 1 will be presented by STALICLA ahead of publication at the BRAIN Foundation Synchrony 2020 conference on December 12, 2020 (online).

“STALICLA is the first company developing precision medicine treatments for a biologically defined subgroup of patients with ASD. A diagnosis of autism must be integrated with other layers of data to capture biologically specific mechanisms, enabling the identification of precision drug candidates to improve on the outcome of clinical trials. STALICLA has built its DEPI drug discovery platform to achieve just this. By defining novel ASD phenotypes based on clinical signs and symptoms and not only on behaviors, STALICLA is creating a precision medicine approach to discovering and developing novel treatments for patients with ASD,” said Lynn Durham, M.Sc. Chief Executive Officer and founder of STALICLA.

“This Phase 1b study for STP1 marks the first time that a precision therapeutic will be investigated in patients with a non-monogenetic cause of ASD. While the trial progresses, STALICLA will continue to drive forward its proprietary and partnered programs to define additional ASD Phenotypes and advance a robust pipeline of therapeutic candidates for ASD and other NDDs,” said, Delphine Charvin, PhD, STALICLA’s Chief Scientific Officer.

“Despite the high prevalence of neurodevelopmental disorders in the U.S. and Europe, most NDDs are diagnosed and treated based on behavioral-based classification systems alone,” said Study Investigator, Craig Erickson, MD, Cincinnati Children’s Hospital Medical Center. “I look forward to investigating the potential of STP1 in the first clinically validated subpopulation of patients with idiopathic ASD.”

The double-blind, placebo-controlled, first-in-human study is being conducted at Cincinnati Children’s Hospital Medical Center in Cincinnati, Ohio. The primary objective of the trial is to evaluate the safety and tolerability of a two-week oral treatment with STP1 in adult patients who match the ASD-Phen1 clinical criteria. Two ascending dose cohorts of approximately 12 patients each will be enrolled. The study will also assess the pharmacokinetic and pharmacodynamic effects of STP1 and includes exploratory efficacy surrogate endpoints.

About ASD Phenotype 1
ASD Phenotype 1 (ASD-Phen1) is a subgroup of patients with autism spectrum disorder which has been identified by STALICLA’s platform and includes as many as 20% of the total ASD population with a non-monogenetic cause. ASD-Phen1 was first validated by an observational clinical trial conducted at the Greenwood Genetic Center (South Carolina, U.S.). ASD-Phen1 criteria were applied to a cohort of 313 patients with ASD. The study led to the identification of patients who matched the required clinical criteria and represented the first clinical validation of the ASD-Phen1 subgroup. Further biological characterization of ASD-Phen1 revealed a specific biological signature, or “fingerprint,” of the patient subgroup that was consistent with the signature proposed by STALICLA’s DEPI drug discovery platform.

About STP1
STALICLA’s investigational new drug, named STP1, is a first-in-class precision medicine being developed as part of the company’s proprietary pipeline for the treatment of ASD for patients within the Phenotype 1 subgroup (ASD-Phen1). STP1 is a novel combination of a pan-PDE inhibitor with anti-inflammatory properties and a modulator of NKCC1. STP1 was identified as a potential match for ASD Phenotype 1 using the DEPI platform, addressing ASD-Phen1 biological dysfunctions and limiting the emergence of compensatory disease pathways. In addition, STP1 has shown a good safety profile in nonclinical toxicology studies. Taken individually, both compounds have also demonstrated good clinical safety and tolerability profiles over a broad range of doses and non-ASD indications.

About STALICLA
STALICLA is reframing neurodevelopmental disorders on the basis of novel insights into their biological underpinnings. By combining real-world patient data and a proprietary systems biology and AI-powered drug discovery platform called DEPI, STALICLA is uncovering novel patient subgroups, enabling targeted clinical development and fueling a rich pipeline of precision therapies. STALICLA has formed a global network of partnerships to bring the first precision medicine treatments to patients with NDDs as efficiently as possible with an initial focus on autism spectrum disorder (ASD). https://stalicla.com/

Contact information

STALICLA
Lynn Durham
lynn.durham@stalicla.com
0041 (0) 78 812 68 98

Media
Kari Watson
MacDougall
kwatson@macbiocom.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SSi Canada Partners with SES Networks to Deliver New Satellite Capacity into Northern Canada18.1.2021 17:40:00 CETPress release

Vital new satellite capacity will be delivered to Canada’s north, including all 25 communities of Nunavut, following a partnership signed between SSi Canada, the developer-operator of QINIQ broadband and SSi Mobile services in Nunavut, and SES Networks, the leader in global content connectivity solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210118005410/en/ SSi Canada Partners with SES Networks to Deliver New Satellite Capacity into Northern Canada (Photo: Business Wire) This partnership comes at a critical time for Nunavut, with the COVID-19 crisis having led to an unprecedented need for reliable internet and mobile communications services as Nunavummiut move increasingly to study, work, and shop online and at home. With growing demand for QINIQ broadband and SSi Mobile services, all 25 communities in Nunavut - and elsewhere in Northern Canada - will benefit from SSi Canada’s multi-year agreement with SES Network

Cloud Contradiction: Despite Security Driving Cloud Adoption, Aptum Study Reveals It’s also the Main Barrier to Cloud Transformation18.1.2021 15:00:00 CETPress release

While 91% of organizations were successful in increasing security as a result of adopting cloud services, it remains a top concern for many. This finding comes from part two of the four-part Cloud Impact Study from Aptum, the global hybrid multi-cloud managed service provider. The report, titled The Security and Compliance Barricade, identifies common security, compliance and governance challenges impacting organizations undergoing cloud transformation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210118005035/en/ Aptum Cloud Impact Study Pt 2.: The Security and Compliance Barricade (Graphic: Business Wire) The independent research reveals that more than half of survey respondents (51%) see security as the main driver behind cloud adoption. However, 38% cite security and data protection as the primary barrier to cloud transformation. Security and compliance play a critical role Part one of the Cloud Impact Study, Bridging

EG Group Selects PDI to Bring Contactless Payments to its North American Sites18.1.2021 13:00:00 CETPress release

PDI (www.pdisoftware.com), a global provider of enterprise software solutions to convenience retailers and petroleum wholesalers, announced it has reached an agreement with EG Group to expand the use of PDI Payments to nearly 1,700 sites across North America. PDI added payments capabilities to its Marketing Cloud Solutions offering last year after acquiring ZipLine, the industry leader for ACH payment and provider of mobile payment technology. The PDI Payments platform currently powers EG Group’s SmartPay Rewards. The rewards program originated with Cumberland Farms—one of several U.S.-based convenience store brands EG Group acquired in recent years—and will soon be rolled out to EG Group’s remaining stores across North America. Customers can download the free app and enjoy a contactless payment experience, whether making purchases in the store or at the pump. PDI will provide the technology to support customer enrollment in SmartPay and deliver ongoing customer service for reward memb

Argo Blockchain PLC announces £22.4 Million Private Placement with Institutional Investors and Mining Capacity Expansion18.1.2021 09:46:00 CETPress release

Argo, the leading cryptocurrency miner based in the UK (LSE:ARB), is pleased to announce that it has entered into a securities purchase agreement for a private placement of its ordinary shares ("Ordinary Shares") to certain institutional investors for gross proceeds of GBP £22.4 million (the "Private Placement"). Pursuant to the Private Placement, the Company will issue 28 million Ordinary Shares (the “Placement Shares”) at a purchase price of GBP £0.80 per Ordinary Share. The Private Placement is limited to those certain institutional investors that have already subscribed and this announcement should not be considered an offer or solicitation to purchase or subscribe for securities in the United States. H.C. Wainwright & Co. is acting as the exclusive placement agent for the Private Placement. The net proceeds of the Private Placement will be used by the Company for working capital and general corporate purposes, including the expansion of the Company’s mining capacity in Q1 and Q2 o

Reply Signs an Agreement with AWS to Develop Industry Solutions18.1.2021 09:30:00 CETPress release

Reply, specialized on new communications channels and digital media, announces today it has signed a Strategic Collaboration Agreement (SCA) with Amazon Web Services (AWS) to develop industry solutions for Financial Services, Manufacturing, Automotive, Retail, Energy, and Telco customers. Through this SCA, the Reply Group of companies dedicated to AWS – Comsysto Reply, Data Reply, Sense Reply, and Storm Reply – will work with organizations of virtually all sizes and allow them to innovate faster and deliver consistent improvements on their business processes using advanced and secure AWS technologies. Reply’s companies dedicated to AWS will offer solutions for highly regulated Financial Services customers, providing them with strategic advisory and security-related consultancy, practices, and frameworks to modernize legacy platforms and solutions designed to address fraud and financial-crime use cases. They will also provide Industrial and Manufacturing customers with the tools they ne

L&T Technology Services Rated as Global Pure-Play ER&D Services Leader by Zinnov18.1.2021 09:00:00 CETPress release

L&T Technology Services Limited (BSE: 540115, NSE: LTTS), a leading global pure-play engineering services company, today announced that it has been rated as a ‘Leader’ in new technologies critical for products and services transformation and also placed in the Leadership Zone across major ER&D Services’ sectors in the Zinnov Zones 2020 ER&D Services study for the fourth consecutive year. LTTS continued to hold the top leadership position in the pure play ER&D Services category in the Zinnov Zones assessments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210118005070/en/ LTTS rated as a Global Leader in ER&D Services in Zinnov Zones 2020. (Graphic: Zinnov) In its latest industry rankings, Zinnov positioned L&T Technology Services as an “Expansive and Established” engineering partner with deep domain competencies in overall ER&D services. LTTS has been rated in the “Leadership Zone” across verticals such as Automotive, Aeros

Guardant Health and Vall d’Hebron Institute of Oncology Announce Partnership to Establish First Guardant-Based Liquid Biopsy Testing Service in Europe18.1.2021 09:00:00 CETPress release

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and Vall d’Hebron Institute of Oncology (VHIO), one of Europe’s leading cancer research organizations, have agreed to enter into a partnership to establish in-house liquid biopsy testing services, using Guardant Health’s industry-leading proprietary digital sequencing platform, at VHIO’s facility in Barcelona, Spain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210118005057/en/ The service is expected to become operational in 2021 and will be available for clinical research and clinical care — starting with private patients, followed by expansion into the public healthcare system over time. “We are pleased to announce this partnership with VHIO which will bring liquid biopsy comprehensive genomic testing to more cancer patients in Spain and beyond,” said Helmy Eltoukhy, Guardant Health CEO. “Our vision is that all cancer patients globally have access